Skip to main content
    F

    Fate Therapeutics Inc (FATE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.14
    -0.14 (-10.94%)

    Market Cap: $155.74M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Fate Therapeutics Inc (FATE) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Fate Therapeutics (FATE) to earn -$0.99 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.58M. Of 11 analysts, 5 rate the stock Buy or Strong Buy, 6 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.45, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 45% of the ratings.

    RatingAnalystsShare
    Strong Buy19.1%
    Buy436.4%
    Hold654.5%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus is unchanged and revenue estimates rise 17.9%.

    Fiscal year ending Dec 31, 2026
    -$0.99
    EPS consensus, revenue $3.58M
    Fiscal year ending Dec 31, 2027
    -$0.99
    EPS consensus, revenue $4.22M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.99-$1.02 to -$0.887$3.58M$3.38M to $4.38M6
    Dec 31, 2027-$0.99-$1.30 to -$0.698$4.22MN/A9

    Quarterly Estimates

    The EPS consensus falls from -$0.25 for the quarter ending Dec 31, 2026 to -$0.27 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.25-$0.27 to -$0.1614$849997N/A14
    Mar 31, 2027-$0.27-$0.33 to -$0.235$671430N/A7

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 9 upward and 4 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202642
    Fiscal year ending Dec 31, 202731
    Quarter ending Mar 31, 202721

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.04.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.99-$1.02-$1.02-$1.02-$1.04N/A
    Fiscal year ending Dec 31, 2027-$0.99-$0.97-$0.97-$0.97-$0.99N/A
    Quarter ending Mar 31, 2027-$0.27-$0.28-$0.28-$0.28-$0.28N/A

    Frequently Asked Questions About FATE

    What is the FATE stock forecast?

    Consensus analyst estimates put Fate Therapeutics's EPS at -$0.99 for the fiscal year ending Dec 31, 2026, on revenue of $3.58M. The consensus rating from 11 analysts is Buy.

    How do analysts rate FATE stock?

    Of 11 analysts covering Fate Therapeutics, 1 rates it Strong Buy, 4 Buy, 6 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from FATE next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.99, with estimates from -$1.02 to -$0.88 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.99, with estimates from -$1.30 to -$0.69 from 8 analysts.

    What revenue do analysts expect from Fate Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.58M, with estimates from $3.38M to $4.38M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.22M.

    How many analysts cover FATE?

    11 analysts rate Fate Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.